Sudo Biosciences, a US biopharmaceutical company, has initiated a Phase I trial for SUDO-550, a potential treatment for neuroinflammatory diseases. The drug, an allosteric TYK2 inhibitor, is designed to penetrate the blood-brain barrier effectively.